Clear Street Starts Coverage on Caribou Biosciences with Buy Rating
Clear Street initiates coverage of Caribou Biosciences with a Buy rating and a $13 price target, highlighting strong CAR-T pipeline potential.
/ 4 items
#CRBU↓
Caribou Vispa-cel Efficacy Matches Autologous CAR-T Therapy
Positive Phase 1 trial data for vispa-cel, an allogeneic (off-the-shelf) CAR-T cell therapy, demonstrates efficacy and durability comparable to traditional autologous treatments, potentially broadening access for patients with large B cell lymphoma.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.